Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as 2-11-2024, 02:00

With the US data center pipeline surging regulated utilities are proving advantaged in meeting demand, says Wood Mackenzie 19-06-2025, 18:00

Talkdesk named a Leader in the 2025 Gartner Magic Quadrant for Contact Center as a Service 11-09-2025, 01:26